Kailera Therapeutics, Inc.
corporate_fare Company Profile
Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KLRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-01, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KLRA spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Kailera's Tri-Agonist Shows Up to 16% Weight Loss in Phase 1
- Kailera Q2 2026: Net Loss Widens to $111.3M, Cash Runway Extended to Mid-2028
- Kailera Reports Q2 2026 Results: $1.17B Cash, Phase 3 Obesity Trials on Track
- Kailera's Oral GLP-1 KAI-7535 Achieves Up to 10.9% Weight Loss in Phase 3 Obesity Trial
- Oral Ribupatide Shows Up To 12.1% Weight Loss in Phase 2, Boosting Kailera's Obesity Pipeline
Short Interest & Short Volume
7.62 days to coverFINRA reported short interest of 5,962,752 shares in KLRA as of the September 15, 2026 settlement, a 5.3% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On October 2, 2026, 56.9% of KLRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for KLRA, detected from its recent SEC filings · based on capital-structure filings through 2026-04-17.
Initial Public Offering Completed · Substantial Capital Raised
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →